Skip to main content
. Author manuscript; available in PMC: 2015 Feb 19.
Published in final edited form as: Neuron. 2014 Jan 23;81(4):873–887. doi: 10.1016/j.neuron.2013.12.011

Figure 7.

Figure 7

Central terminal TRPV1 and 5-HT3AR facilitate synaptic transmission to V3 lamina II neurons of the ipsilateral Vc after CCI-ION. (A) Upper: representative traces showed mEPSCs in one neuron of V3 division of the Vc from naïve or CCI-treated mice at 14d. Bottom: summarized mEPSCs frequency (left) and amplitude (right) from V3 neurons in the Vc of different groups (n=5–6 neurons per group). *p<0.05; ***p<0.001 versus naïve. (B) Original traces show mEPSCs during baseline control, application of selective TRPV1 antagonist AMG9810 (10 μM, 3 min) into Vc slices, and washout in one V3 neuron of the Vc from CCI 14 day-treated mice (right). (C) Original traces showed mEPSCs during baseline control and application of 5-HT3AR antagonist Y25130 (5 μM, 3 min) in one V3 lamina II neuron of Vc from CCI 14d-treated mice. (D) Normalized to the pre-drug treatment baseline mEPSCs, pooled data show significant reduction of frequencies (left) of mEPSCs in V3 neurons with blockade of Vc TRPV1 (n=9) or 5-HT3AR function (n=6) 14 days after CCI. However, there was no change of the amplitudes of mEPSCs (right). *p<0.05, ***p<0.001 vs. before drugs. (E) Upper: Typical traces showed sEPSCs (in the absence of TTX) during control, application of 5-HT3AR agonist SR57227 (10 μM, 3 min), pretreatment of AMG9810 plus application of SR57227, and application of AMG9810 alone in one V3 neuron of the Vc slices from naïve mice. Bottom: Normalized to the baseline sEPSCs, pooled data demonstrated that 10 μM SR57227-induced increase of the frequency (the left) but not the amplitude (the right) of sEPSCs in 7 neurons from the Vc slices of naïve mice. Pretreatment of AMG9810 attenuated SR57227-induced increase of the frequency of sEPSCs without effects on baseline control. ***p<0.001, vs. baseline control; #p<0.05 vs. SR57227 alone. (F) Effects of intra-Vc injection of AMG9810 (5 pmol/0.5μl) on CCI-induced mechanical hyperalgesia 14 days after nerve injury (n=6–8 mice per groups). **p<0.01, vs. baseline; #, p<0.05 vs. before drug treatment.